Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

CONTEXT: Denosumab 60 mg sc injection every 6 months for 36 months was well tolerated and effective in reducing the incidence of vertebral, nonvertebral, and hip fracture in predominantly Caucasian postmenopausal women with osteoporosis. OBJECTIVE: The objective of this phase 3 fracture study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Toshitaka, Matsumoto, Toshio, Sugimoto, Toshitsugu, Hosoi, Takayuki, Miki, Takami, Gorai, Itsuo, Yoshikawa, Hideki, Tanaka, Yoshiya, Tanaka, Sakae, Sone, Teruki, Nakano, Tetsuo, Ito, Masako, Matsui, Shigeyuki, Yoneda, Toshiyuki, Takami, Hideo, Watanabe, Ko, Osakabe, Taisuke, Shiraki, Masataka, Fukunaga, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2014
Materias:
Endocrine Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191553/
https://www.ncbi.nlm.nih.gov/pubmed/24646104
http://dx.doi.org/10.1210/jc.2013-4175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191553/
https://www.ncbi.nlm.nih.gov/pubmed/24646104
http://dx.doi.org/10.1210/jc.2013-4175

Ejemplares similares